CliffBio
small molecule

ISENTRESS

RALTEGRAVIR POTASSIUM

Loss of exclusivitySeptember 2029latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Drug detail

Brand nameISENTRESS
Active ingredientRALTEGRAVIR POTASSIUM
StrengthEQ 100MG BASE/PACKET
Dosage formPOWDER
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2013
Marketing statusRX

Listed patents

PatentExpiresType
7754731*PEDSeptember 2029—
7754731March 2029substance, product

More from MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ISENTRESS patent cliff — loss of exclusivity September 2029 | CliffBio